Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells. 1990

T Igawa, and T Tani, and T Chijiwa, and T Shiragiku, and S Shimidzu, and K Kawamura, and S Kato, and F Unemi, and Y Kimura
Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd., Japan.

We developed the new system in which the platelet aggregation was detected turbidimetrically using glass cuvettes which were coated cultured vascular endothelial cells. Using this system, we evaluated the effect of cilostazol, having a selective inhibitory effect on cAMP-PDE, on the ADP-induced platelet aggregation in the presence of endothelial cells. Cilostazol inhibited the platelet aggregation dose-dependently in the presence or absence of endothelial cells. The inhibitory effect of cilostazol on platelet aggregation was potentiated by the presence of endothelial cells, and the slope of the dose-response curves were identified to be as the same between both experiments in the presence and the absence of endothelial cells. The pretreatment of endothelial cells with aspirin reversed the potentiated inhibitory effect of cilostazol on the platelet aggregation with endothelial cells. The amount of 6-keto-prostaglandin F1 alpha accumulated in the cuvette was reduced in this condition. On the other hand, the inhibitory effect of prostaglandin E1 on the platelet aggregation was not potentiated by the presence of endothelial cells. These results suggest that the endothelium-derived prostacyclin plays a role on the potentiation of anti-platelet aggregatory effect of cilostazol.

UI MeSH Term Description Entries
D009391 Nephelometry and Turbidimetry Chemical analysis based on the phenomenon whereby light, passing through a medium with dispersed particles of a different refractive index from that of the medium, is attenuated in intensity by scattering. In turbidimetry, the intensity of light transmitted through the medium, the unscattered light, is measured. In nephelometry, the intensity of the scattered light is measured, usually, but not necessarily, at right angles to the incident light beam. Turbidimetry,Nephelometry,Turbidimetry and Nephelometry
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077407 Cilostazol A quinoline and tetrazole derivative that acts as a phosphodiesterase type 3 inhibitor, with anti-platelet and vasodilating activity. It is used in the treatment of PERIPHERAL VASCULAR DISEASES; ISCHEMIC HEART DISEASE; and in the prevention of stroke. 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone,OPC 13013,OPC-13013,Pletal
D000244 Adenosine Diphosphate Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position. ADP,Adenosine Pyrophosphate,Magnesium ADP,MgADP,Adenosine 5'-Pyrophosphate,5'-Pyrophosphate, Adenosine,ADP, Magnesium,Adenosine 5' Pyrophosphate,Diphosphate, Adenosine,Pyrophosphate, Adenosine
D000527 Alprostadil A potent vasodilator agent that increases peripheral blood flow. PGE1,Prostaglandin E1,Caverject,Edex,Lipo-PGE1,Minprog,Muse,PGE1alpha,Prostaglandin E1alpha,Prostavasin,Prostin VR,Prostine VR,Sugiran,Vasaprostan,Viridal,Lipo PGE1

Related Publications

T Igawa, and T Tani, and T Chijiwa, and T Shiragiku, and S Shimidzu, and K Kawamura, and S Kato, and F Unemi, and Y Kimura
October 1993, Stroke,
T Igawa, and T Tani, and T Chijiwa, and T Shiragiku, and S Shimidzu, and K Kawamura, and S Kato, and F Unemi, and Y Kimura
December 1976, Revista espanola de fisiologia,
T Igawa, and T Tani, and T Chijiwa, and T Shiragiku, and S Shimidzu, and K Kawamura, and S Kato, and F Unemi, and Y Kimura
June 1988, Thrombosis research,
T Igawa, and T Tani, and T Chijiwa, and T Shiragiku, and S Shimidzu, and K Kawamura, and S Kato, and F Unemi, and Y Kimura
January 1966, Hemostase,
T Igawa, and T Tani, and T Chijiwa, and T Shiragiku, and S Shimidzu, and K Kawamura, and S Kato, and F Unemi, and Y Kimura
August 2006, Biochemical pharmacology,
T Igawa, and T Tani, and T Chijiwa, and T Shiragiku, and S Shimidzu, and K Kawamura, and S Kato, and F Unemi, and Y Kimura
April 1980, Cancer research,
T Igawa, and T Tani, and T Chijiwa, and T Shiragiku, and S Shimidzu, and K Kawamura, and S Kato, and F Unemi, and Y Kimura
April 1996, Biochemical and molecular medicine,
T Igawa, and T Tani, and T Chijiwa, and T Shiragiku, and S Shimidzu, and K Kawamura, and S Kato, and F Unemi, and Y Kimura
December 1996, Thrombosis and haemostasis,
T Igawa, and T Tani, and T Chijiwa, and T Shiragiku, and S Shimidzu, and K Kawamura, and S Kato, and F Unemi, and Y Kimura
December 1994, Farmaco (Societa chimica italiana : 1989),
T Igawa, and T Tani, and T Chijiwa, and T Shiragiku, and S Shimidzu, and K Kawamura, and S Kato, and F Unemi, and Y Kimura
January 1985, Thrombosis research,
Copied contents to your clipboard!